303384
Health Disparities under black market transition of health system in North Korea
Given the inaccessibility to North Korea, relevant data will be gathered from i) Literature review of published and unpublished documents on the current state of marketization, population health, health risks, and health systems in North Korea; as well as ii) Secondary data analysis (including data from UN and international organizations, NGOs, and academic institutions); iii) twenties qualitative interviews with North Korean health professionals and relevant scholars and policy makers working inside and outside North Korea.
Learning Areas:
Other professions or practice related to public healthProvision of health care to the public
Public health or related laws, regulations, standards, or guidelines
Public health or related organizational policy, standards, or other guidelines
Public health or related public policy
Learning Objectives:
Discuss politics of stagnating health reform in North Korea, by describing (i) health disparities in recent black marketization of health system in chronic economic isolation; and (ii) analyzing poorly governed, fragmented and discriminative health reforms in-between socialist and capitalist policies.
Keyword(s): Politics, Privatization
Qualified on the content I am responsible for because: Jiho Cha, MD MSc is a humanitarian physician working for protecting North Korean Health in last 10 years through key governmental and non-governmental organizations, including (but not limited to) Human Rights Watch; Doctors Without Borders (MSF Switzerland, Mission of North Korea); MEDIPEACE;International Organization for Migration (IOM), South Korean Ministry of Unification's Settlement Support Center for the Displaced North Koreans (Hanawon) where he has been the principal or co-principal of both humanitarian operations and researches.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.